alendronate has been researched along with Nephrotic Syndrome in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Nephrotic Syndrome: A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate is a widely used bisphosphonate in the treatment of osteoporosis." | 7.78 | Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis. ( Kara, E; Ozagari, A; Taninmis, H; Unsal, A; Yilmaz, M, 2012) |
| "Alendronate is a widely used bisphosphonate in the treatment of osteoporosis." | 3.78 | Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis. ( Kara, E; Ozagari, A; Taninmis, H; Unsal, A; Yilmaz, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miura, N | 1 |
| Mizuno, N | 1 |
| Aoyama, R | 1 |
| Kitagawa, W | 1 |
| Yamada, H | 1 |
| Nishikawa, K | 1 |
| Imai, H | 1 |
| Yilmaz, M | 1 |
| Taninmis, H | 1 |
| Kara, E | 1 |
| Ozagari, A | 1 |
| Unsal, A | 1 |
2 other studies available for alendronate and Nephrotic Syndrome
| Article | Year |
|---|---|
Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
Topics: Acute Kidney Injury; Administration, Oral; Alendronate; Blood Component Removal; Bone Density Conser | 2009 |
Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Humans; Male; Nephrotic Syndrome; Osteoporosis | 2012 |